BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37900646)

  • 21. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03.
    Toledano I; Graff P; Serre A; Boisselier P; Bensadoun RJ; Ortholan C; Pommier P; Racadot S; Calais G; Alfonsi M; Favrel V; Giraud P; Lapeyre M
    Radiother Oncol; 2012 Apr; 103(1):57-62. PubMed ID: 22296746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
    Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
    Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer.
    Mayo ZS; Ilori EO; Matia B; Smile TD; Fleming CW; Reddy CA; Scharpf J; Lamarre ED; Prendes BL; Ku J; Burkey BB; Joshi NP; Woody NM; Koyfman SA; Campbell SR
    Anticancer Res; 2022 Apr; 42(4):1845-1849. PubMed ID: 35347002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Sher DJ; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Balboni T; Allen A; Tishler RB
    Cancer; 2010 Oct; 116(20):4761-8. PubMed ID: 20572036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
    Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is planned neck dissection necessary for head and neck cancer after intensity-modulated radiotherapy?
    Yao M; Hoffman HT; Chang K; Funk GF; Smith RB; Tan H; Clamon GH; Dornfeld K; Buatti JM
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):707-13. PubMed ID: 17379453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
    Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
    Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.
    Lambrecht M; Nevens D; Nuyts S
    Strahlenther Onkol; 2013 Mar; 189(3):223-9. PubMed ID: 23319256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMRT: preliminary results in a series of advanced head-and-neck cancer patients.
    Vila Capel A; Vilar Palop J; Pedro Olivé A; Sanchez-Reyes Fernandez A; Vayreda Ribera J; Julià Sanahuja JC; Pérez de Olaguer Agustín J; Artola Codina N; Moya Cascant LM; Rubio Calatayud E; Carrera Domenech G
    Clin Transl Oncol; 2013 Mar; 15(3):233-42. PubMed ID: 22855193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
    Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
    JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck.
    Yang H; Diao LQ; Shi M; Ma R; Wang JH; Li JP; Xiao F; Xue Y; Xu M; Zhou B
    Biologics; 2013; 7():223-9. PubMed ID: 24204121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definitive radiotherapy in patients of synchronous esophageal and head and neck cancer-treatment outcome and toxicity.
    Sarma G; Nath J; Medhi PP; Momin FJ; Kalita AK; Bhattacharyya M
    Cancer Treat Res Commun; 2020; 25():100248. PubMed ID: 33254043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospital.
    Rumley CN; Nedev N; Sharples K; Lee J; Lamb DS
    J Med Radiat Sci; 2016 Jun; 63(2):96-103. PubMed ID: 27350889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.
    Ward MC; Ross RB; Koyfman SA; Lorenz R; Lamarre ED; Scharpf J; Burkey BB; Joshi NP; Woody NM; Prendes B; Houston N; Reddy CA; Greskovich JF; Adelstein DJ
    JAMA Otolaryngol Head Neck Surg; 2016 Dec; 142(12):1164-1170. PubMed ID: 27438230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial.
    Gupta T; Sinha S; Ghosh-Laskar S; Budrukkar A; Mummudi N; Swain M; Phurailatpam R; Prabhash K; Agarwal JP
    Radiat Oncol; 2020 Sep; 15(1):218. PubMed ID: 32938468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Evaluation of Taste Function in Patients With Head and Neck Cancer Receiving Intensity-Modulated Radiotherapy.
    Chen WC; Hsu CM; Tsai YT; Lin MH; Tsai MS; Chang GH; Lai CH; Fang F; Chen MF
    JAMA Otolaryngol Head Neck Surg; 2022 Jul; 148(7):604-611. PubMed ID: 35616981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implications for cancer control program in India.
    Chauhan AS; Prinja S; Ghoshal S; Verma R
    Int J Technol Assess Health Care; 2020 Oct; 36(5):492-499. PubMed ID: 32962782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous Integrated Boost Radiotherapy in Unresectable Stage IV (M0) Head and Neck Squamous Cell Cancer Patients: Daily Clinical Practice.
    Iatì G; Parisi S; Santacaterina A; Pontoriero A; Cacciola A; Brogna A; Platania A; Palazzolo C; Cambareri D; Davì V; Napoli I; Lillo S; Severo C; Tamburella C; Vadalà R; Delia P; Pergolizzi S
    Rep Pract Oncol Radiother; 2020; 25(3):399-404. PubMed ID: 32368191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.